China's diabetes growth could boost Merck, Sanofi, Novo; Novartis wins new Votubia approval;

@FiercePharma: FDA backs Boehringer Ingelheim's Pradaxa on safety. Big caution, though, in bold type: Use as directed. More | Follow @FiercePharma

> China's diabetes-drug market is swelling to $3.2 billion as it becomes the "world's capital" for the disease, opening opportunites for drugs from Merck ($MRK), Sanofi ($SNY) and Novo Nordisk ($NVO). Report

> Novartis ($NVS) won European approval for its cancer drug Votubia--sold as Afinitor in the U.S.--as a treatment for non-cancerous kidney tumors in patients with tuberous sclerosis complex. Release | Report

> As a sister company to the meningitis-linked compounding pharmacy extended its shutdown, the FDA scrambled to fill supply gaps. Report

> A New York jury ordered Novartis ($NVS) to pay $10.45 million to a woman who suffered jawbone damage after taking its bone drug Zometa. Report

> Standard & Poor's assigned a BB- rating to Rottapharm's planned offering of €400 million ($511.5 million) in senior unsecured notes, calling the company's outlook "stable." Report

> A New Jersey judge refused to transfer RP Healthcare's antitrust case against Pfizer ($PFE) and Ranbaxy Laboratories to California. Report

Medical Device News

 @FierceMedDev: Some regulatory decisions on devices and drugs may face delays. Blame Hurricane Sandy. More | Follow @FierceMedDev

 @MarkHFierce: More woes for Abiomed. Shareholders will now investigate the company's marketing and labeling of its Impella 2.5. More | Follow @MarkHFierce

 @DamianFierce: The Indian clinical trial industry will continue to explode, but only if it cleans up its act, TOI says. More | Follow @DamianFierce

> For diabetics, bypass beats stents in massive 5-year study. Article

> New tech could harvest heartbeat to power pacemakers. Item

> Ishrak: Medtronic must establish economic value to drive growth. Story

Biotech News

 @FierceBiotech: Merck finds pharma research results with online competition. More | Follow @FierceBiotech

 @JohnCFierce: BioMarin shares pop on strong pivotal data for rare disease drug. More | Follow @JohnCFierce

 @RyanMFierce: Winners named in Merck's online competition involving pharma research, Kaggle blog. More | Follow @RyanMFierce

> FDA review endorses efficacy of Novartis' new drug for Cushing's disease. Story

> Ex-Pfizer crew snags $27M financing for U.K. drugs startup. News

> Experts rip chelation heart study despite a hint of efficacy. Article

Biotech IT News

> Roche seeks advances in cloud computing for cancer drug research. News

> Sanofi deal bolsters Medidata in record quarter for revenue. Article

> Titan slays Jaguar in computing comparison, open to R&D comers. Report

>Merck finds pharma research results with online competition. Story

CRO News

> Quintiles chief: CROs need to jump on sequencing bandwagon. Item

> GE pours $23M into Biocon's CRO as it plots public offering. Story

> Icon soars in Q3, plots NASDAQ jump. Report

> Cyprotex snags deal with Pfizer for toxicology. More

> Charles River pays $27M for majority of Chinese firm. News

And Finally... Suicide rates in the U.S. rose sharply during the economic crisis, a Lancet study found. Report

Suggested Articles

Stephen Hahn, an oncologist who served as the chief medical officer for the MD Anderson Cancer Center, has secured Senate confirmation as FDA head.

As BMS searches for bright spots in its Opdivo-chemo combo fail from June, it’s zeroing in on squamous lung cancer patients who seemed to benefit.

The FDA's ad watchdog served its most serious violation to Alkermes Wednesday—and it took the unusual step of announcing that violation to the world.